Best Oncology Companies in Connecticut, United States
The 38 best Oncology companies in Connecticut, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Treeline Biosciences.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Connecticut
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Treeline Biosciences Developer of transformative precision medicines to treat cancer 64Funding top 18%Patents top 21%Innovation top 24%Moat top 26% All 9 signals ▾Fundingtop 18% Patentstop 21% Innovationtop 24% Moattop 26% Talenttop 38% Techtop 48% Marketbottom 45% Globalbottom 40% Newsbottom 31% Funding: Raised $895M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 103 patents matched (strict assignee match) · 103 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $895M | 12 mo ago | 148 | Joshua Bilenker Co-Founder & CEO | 103 patents Patents concentrated in chemistry & materials | — |
| 2 | Halda Therapeutics Developer of precision therapeutics for cancer treatment | $217M | 25 mo ago | 30 | Craig Crews Founder & CEO | — | — |
| 3 | IsoPlexis Developer of multiplexed single-cell analysis tools for the diagnostics and life science research | $186M | 68 mo ago | 195 | — | 72 patents Single-cell immune profiling and multiplexed analysis of cellular therapeutics | — |
| 4 | NextCure Developer of next-generation immuno-oncology-based drugs 69News top 21%Funding top 23%Patents top 25%Moat top 26% All 11 signals ▾Newstop 21% Fundingtop 23% Patentstop 25% Moattop 26% Growthtop 30% Innovationtop 32% Fin. healthtop 43% Markettop 44% Partnerstop 45% Techbottom 46% Globalbottom 42% News: 7 BI events in 12 mo (of 19 tracked, 5 types) · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $175M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $175M | 10 mo ago | 87 | — | 77 patents Novel immune‑checkpoint antibody therapeutics for cancer immunotherapy. | — |
| 5 | Kolltan Pharmaceuticals Using antibody to target different tyrosine kinase receptors to treat cancer. | $141M | 149 mo ago | 41 | — | — | — |
| 6 | Cybrexa Therapeutics Developer of therapeutics that target the tumour microenvironment | $118M | 50 mo ago | 19 | — | — | — |
| 7 | Arvinas Developer of small molecule drugs to target and degrade disease causing proteins | $100M | 85 mo ago | 266 266 → 305 (+15%) | — | 153 patents Targeted protein degradation (PROTAC) therapeutics for hormone receptors and other disease proteins | — |
| 8 | OrphAI Therapeutics Developer of treatments for rare orphan conditions | $98M | 113 mo ago | 16 | Brigette Roberts CEO | — | — |
| 9 | Transgenomic Molecular Diagnostics in cardiology, oncology, and inherited diseases | $72M | 112 mo ago | 53 | — | 51 patents Enrichment and detection of low-frequency DNA variants using cold-PCR for diagnostic sequencing | — |
| 10 | Simcha Therapeutics Developer of therapeutics with anti-tumor effect | $65M | 15 mo ago | 15 | Aaron Ring Founder | — | — |
| 11 | Loxo Oncology Developing TRK inhibitors (tyrosine kinase) for the treatment of solid tumors. | $57M | 148 mo ago | 75 | — | 465 patents Small-molecule RET and BTK kinase inhibitors, including polymorphs, formulations, and synthesis methods. | — |
| 12 | CGI Pharmaceuticals Small molecule therapeutics for multiple oncology and immunology-based indications | $44M | 271 mo ago | 38 | Ira Mellman Founder | 133 patents Patents concentrated in chemistry & materials | — |
| 13 | Azitra Developer of micriobiome based therapeutics solution for treating skin atopic dermatitis or eczema | $37M | 68 mo ago | 17 17 → 13 (-24%) | Francisco Salva CEO | 110 patents Engineered live microbial therapeutics for dermatological disease treatment | — |
| 14 | Ikonisys Developer of non-invasive diagnostic tests for cancer detection | $35M | 18 mo ago | 8 | Michael Kilpatrick Founder | 235 patents Automated fluorescence imaging and digital pathology for cancer detection and specimen analysis | — |
| 15 | Kleo Pharmaceuticals Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune… | $35M | 74 mo ago | 20 | — | — | — |
| 16 | Intensity Therapeutics Reformulating oncology drugs for treating late stage solid tumors | $21M | 94 mo ago | 7 | Lew Bender Founder | — | — |
| 17 | Cellinfinity Bio Developer of cell therapies for cancer treatment | $13M | 20 mo ago | 9 | Sidi Chen Founder | — | — |
| 18 | Modifi Bio Developer of therapeutics for the treatment of cancer | $12M | 24 mo ago | 11 | Ranjit Bindra Co-Founder | — | — |
| 19 | DotLab Provider of a molecular diagnostic testing tool for endometriosis in women | $10M | 86 mo ago | 11 | Heather Bowerman Founder & CEO | — | — |
| 20 | Cantex Developing oral treatments for cancer and inflammatory lung diseases | $8M | 148 mo ago | 6 | — | 24 patents Pipe end flare sealing devices and adjustable electrical enclosure mounting solutions | — |
| 21 | Osmol Therapeutics Developer of treatments for chemotherapy-induced peripheral neuropathy (CIPN) | $8M | 53 mo ago | 2 | Barbara Ehrlich Founder | — | — |
| 22 | Bioarray Gene expression- based diagnostics for cancer. | $7M | 107 mo ago | 7 | — | 286 patents Multiplexed nucleic acid typing and microparticle array platforms for genetic analysis | — |
| 23 | Mira Dx miRNA-based diagnostic tests | $7M | 192 mo ago | 13 13 → 29 (+123%) | Joanne Weidhaas Chairperson of the Board and Co-Founder | 44 patents Predictive cancer biomarkers for immunotherapy response and radiation toxicity assessment. | — |
| 24 | Lumeda Developer of photodynamic therapy device for treating lung cancer | $5M | 67 mo ago | 10 | Paul Sanders Co-Founder | 45 patents Provides advanced optical delivery systems for photodynamic cancer therapy and imaging | — |
| 25 | Precipio Diagnostics Provider of cancer diagnostics and second opinion tools | $5M | 106 mo ago | 56 | — | — | — |
| 26 | CytoVeris Developer of optical based guided surgical tools for cancer surgery | $4M | 58 mo ago | 22 | Alan Kersey President & CEO | 54 patents Intraoperative fluorescence, Raman, and multispectral imaging for cancer margin detection | — |
| 27 | OmniCyte Developer of targeted therapies for the treatment of cancer | $256K | 71 mo ago | 3 | Angel Pellicer Co-Founder | 19 patents Viral glycoprotein-modified fusion protein cancer vaccines for tumor antigen immunotherapy | — |
| 28 | Encapsulate Manufacturer of microfluidic-based tumour on chip technology | $256K | 52 mo ago | 8 | Armin Rad Co-Founder & CEO | — | — |
| 29 | QCDx Developer of instruments for the detection of rare cells in the blood circulation | $130K | 16 mo ago | 9 | — | 23 patents Liquid biopsy diagnostics: detecting circulating tumor cells, viral pathogens, and biomarkers in biological samples. | — |
Top 12 Oncology companies in Connecticut
#1
Series A · Stamford, Connecticut · founded 2021 · 148 employees$895.4Mraised▾
Developer of transformative precision medicines to treat cancer. The company's drug discovery platform includes mechanistic biology, medicinal chemistry, computational science, structural biology & protein science.
- Aug 2025Series A$200.1M
- Oct 2024Series A$421.8M
- Sep 2022Series A$262M
- Apr 2021Series A$211.7M
#2
Public · New Haven, Connecticut · founded 2015 · 87 employees$175.4Mraised▾
Developer of next-generation immuno-oncology-based drugs. The proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. The pipeline candidates include NC318 for tumor and macrophages, NC410 for myeloid and T-cells, NC762 for tumors, NC252 for leukemia cells, and others.
- Nov 2025Post IPO$21.5M
- Nov 2018Series B$93.4M
- Nov 2018Series A$15M
- Jan 2016Series A$67M
#3
Series B · New Haven, Connecticut · founded 2018 · 15 employees$65Mraised▾
Developer of therapeutics with anti-tumor effect. The lead candidate of the company is ST-067, based on the immune system and IL-18 cytokine which is having potent antitumor effects. The company claims to have shown a positive response on the animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors.
- Jun 2025Series B$7.1M
- Jan 2022Series B$40M
- Jun 2020Series A$25M
- Jul 2018Series A$4.4M
#4
Public · New Haven, Connecticut · founded 1999 · 8 employees$35.2Mraised▾
Developer of non-invasive diagnostic tests for cancer detection. The company has developed oncoFISH for the detection of cancer-related chromosomal abnormalities, oncoFISH bladder for the diagnosis of bladder cancer, oncoFISH cervical, oncoFISH PTEN, and oncoFISH ALK. Also developed a proprietary Ikoniscope digital microscope to deliver highly accurate and reliable detection of rare cells.
- Feb 2025Post IPO$524.8K
- Nov 2024Post IPO$211.2K
- Dec 2023Post IPO$1.1M
- Jul 2012Series C$1.4M
#5
Acquired · New Haven, Connecticut · founded 2019 · 30 employees$216.7Mraised▾
Developer of precision therapeutics for cancer treatment. It offers a lead drug candidate which is a RIPTAC therapeutic that utilizes androgen receptor as a targeting protein to selectively deliver the drug for the treatment of metastatic, castrate-resistant prostate cancer, and tumors.
- Aug 2024Series B$126.5M
- May 2024Series B$24.2M
- Dec 2021Series B$41M
- Feb 2019Series A$25M
#6
Series B · West Haven, Connecticut · founded 2021 · 9 employees$13.2Mraised▾
Developer of cell therapies for cancer treatment. It offers genetically engineered T cell, NK cell, and other immune cell-based therapies against multiple malignancies which includes solid tumors.
- Jan 2025Grant (prize money)$400K
- Aug 2022Series B$13.2M
#7
Acquired · New Haven, Connecticut · founded 2021 · 11 employees$11.7Mraised▾
Developer of therapeutics for the treatment of cancer. The company focuses on developing therapeutics that uniquely target specific acquired cancer cell DNA mutations for the treatment of all cancer types.
- Aug 2024Seed$995.5K
- Oct 2023Seed$4.3M
- Jul 2022Seed$6.4M
#8
Series C · New Haven, Connecticut · founded 2016 · 19 employees$118.1Mraised▾
Developer of therapeutics that target the tumor microenvironment. The company is developing a new class of small molecule DNA repair inhibitors by using alphalex tumor-targeting platform. The candidate CBX-12 an alphalex-exatecan conjugate for the treatment of solid tumors. Other candidates include CBX-13, CBX-14, and CBX-15 for multiple cancer.
- Jun 2022Series C$40.2M
- Nov 2021Series C$31.2M
- Mar 2021Series B$25M
- Jan 2020Series B$1.7M
#9
Acquired · New Haven, Connecticut · founded 2012 · 195 employees$185.9Mraised▾
Developer of multiplexed single-cell analysis tools for diagnostics and life science research. Their specialties include 'secretome analysis for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research, and oncology.
- Jan 2021Conventional Debt$50M
- Jan 2021Series D$92.5M
- Jun 2020Grant (prize money)$2M
- Jan 2020Series C$20M
#10
Seed · Farmington, Connecticut · founded 2016 · 9 employees$130Kraised▾
Developer of instruments for the detection of rare cells in the blood circulation. The products of the company include RareScope a Rare Cell Detection, RarePrep holds cells immobilized in the life-sustaining hydrogel, RarePicker, and RareVivo.
- May 2025Conventional Debt$5.3M
- May 2025Seed$1.7M
- Dec 2017Seed$130K
#11
Acqui-Hired · New Haven, Connecticut · founded 2007 · 41 employees$141Mraised▾
Kolltan Pharmaceuticals discovers and develops novel antibody-based drugs targeting receptor tyrosine kinases (RTK) for the treatment of cancer and other diseases. Its lead product candidate includes KTN3379, a monoclonal antibody targeting an epidermal growth factor receptor (EGFR) in development for adult patients with advanced solid tumors. The company is also developing KTN0158, a KIT protein (Reverse Tyrosine kinase) inhibitor for the treatment of neurofibromatosis type 1 and other inflammatory diseases; and KIT-ADC, an antibody drug conjugate for oncology treatment, as well as a range of research programs targeting RTKs.
- Mar 2014Series D$60M
- Mar 2012Series C$25M
- Sep 2010Series B$6M
- Jan 2010Series B$10M
#12
Public · New Haven, Connecticut · founded 2013 · 266 employees$100.1Mraised▾
Developer of small molecule drugs to target and degrade disease causing proteins. It offer therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its protein degradation platform uses bifunctional small molecules, Proteolysis-Targeting Chimeras (PROTACs), to target proteins for removal from the cell. PROTACs recruit an E3 ubiquitin ligase to a specific targeted protein, thereby labelling that protein for elimination by the Ubiquitin/Proteasome System (UPS).
- Jul 2019Post IPO$32.5M
- Apr 2018Series C$55M
- Oct 2015Series B$41.6M
- Jul 2013Seed$3.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
What Connecticut researches in oncology
- University of Connecticut13
- Connecticut Children\'s Medical Center5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.